Immunotherapy Drugs Market Analysis

The global immunotherapy drugs market is segmented by therapy area into cancer, infectious diseases, inflammatory & autoimmune diseases, and others. Among these segments, the cancer segment is anticipated to register the largest market share by the end of 2021. The growth of the segment can be attributed to the growing prevalence of cancer diseases globally, and the increasing need for prevention and cure of such chronic diseases, backed by the rising burden and the risks associated with the disease. According to the statistics by the World Health Organization (WHO), in the year 2018, around 9.6 million deaths was caused due to cancer, a disease which is also the second leading cause of death around the world. Moreover, increasing research and advancements in immune-oncology, along with the growing research for immunotherapy cure for stage-4 cancer, are some of the additional factors anticipated to drive the growth of the segment during the forecast period.

Our in-depth analysis of the global market includes the following segments

By Type

Targeted Immunotherapies
Monoclonal Antibodies
Naked Monoclonal Antibodies
Conjugated Monoclonal Antibodies
Bispecific Monoclonal Antibodies
Checkpoint Inhibitors or Tumor-Agnostic Treatments
PD-1
Pembrolizumab (Keytruda)
Nivolumab (Opdivo)
Cemiplimab (Libtayo)
PD-L1
Atezolizumab (Tecentriq)
Durvalumab (Imfinzi)
Avelumab (Bavencio)
CTLA-4 Inhibitor
Ipilimumab (Yervoy)
Therapeutic Cancer Vaccines
Preventive
Cervarix, Gardasil, and Gardasil-9
Hepatitis B (HBV) Vaccine (HEPLISAV-B)
Treatment
Sipuleucel-T (Provenge)
Talimogene Laherparepvec (T-VEC) (Imlygic)
Bacillus Calmette-Guerin (BCG)
Adoptive Cell Therapies
Tumor-Infiltrating Lymphocyte (TIL) Therapy
Engineered T-Cell Receptor (TCR) Therapy
CAR T-Cell Therapy
Natural Killer (NK) Cell Therapy
Oncolytic Virus Therapy
Immune System Modulators
Interleukins
Interferons
Immunomodulators (IMiDs)
Imiquimod (Aldara, Zyclara)
Lenalidomide (Revlimid)
Pomalidomide (Pomalyst)
Thalidomide (Thalomid, and Contergan)
Bacillus Calmette-Guerin or BCG
Others

By Therapy Area

Cancer
Infectious Diseases
Inflammatory & Autoimmune Diseases
Others

Frequently Asked Questions (FAQ)

In the year 2025, the industry size of immunotherapy drugs is estimated at USD 327.72 billion.

Immunotherapy Drugs Market size was valued at USD 290.22 billion in 2024 and is set to exceed USD 1.82 trillion by 2037, registering over 15.2% CAGR during the forecast period i.e., between 2025-2037.

North America industry is predicted to account for largest revenue share by 2037, on the back of presence of several key players, along with growing number of new cancer cases registered every year in the region.

The major players in the market are Merck & Co., Inc., Gilead Sciences, Inc., Pfizer Inc., AstraZeneca PLC, Johnson & Johnson Services, Inc., Bristol-Myers Squibb Company, GlaxoSmithKline plc, and others.

Immunotherapy Drugs Market Analysis